文献速递痛风与晶体性关节病

口服司美格鲁肽对2型糖尿病患者血清尿酸水平的影响:URISEMA回顾性真实世界分析

Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).
PubMed 文献 · Semin Arthritis Rheum · 2025-08-07

该回顾性观察研究纳入236例接受口服司美格鲁肽治疗的2型糖尿病患者,主要终点为随访12个月时血清尿酸低于6 mg/dL。6个月和12个月时分别有70.7%和76%的患者达到该目标;12个月时血清尿酸平均下降0.2 mg/dL(p=0.01),基线尿酸>6 mg/dL者下降更明显。

要点

  • 口服司美格鲁肽治疗6个月和12个月时,分别有70.7%和76%的患者血清尿酸<6 mg/dL。
  • 12个月随访时血清尿酸平均下降0.2 mg/dL(p=0.01),6个月时下降0.1 mg/dL(p=0.52)。
  • 基线尿酸>6 mg/dL者降幅更大:6个月降0.6 mg/dL、12个月降0.8 mg/dL(均p<0.001)。

核心结论

  • 真实世界背景下,口服司美格鲁肽可使2型糖尿病患者血清尿酸轻中度下降,降幅与基线高尿酸血症及从DPP-4抑制剂转换相关。

研究设计与样本

  • 回顾性观察性研究,纳入236例接受口服司美格鲁肽处方的2型糖尿病患者,中位年龄64岁、BMI 33.8 kg/m²、HbA1c 7.6%,女性占40.7%,52.3%使用SGLT2抑制剂。

主要发现

  • 基线血清尿酸为5.2 mg/dL,66.1%的患者血清尿酸<6 mg/dL,23.7%存在高尿酸血症。
  • 口服司美格鲁肽治疗6个月和12个月时,分别有70.7%和76%的患者血清尿酸<6 mg/dL。
  • 多因素校正后,仅基线血清尿酸≥7 mg/dL(OR 4.54,95%CI 1.08-19.25)和从DPP-4抑制剂转换(OR 6.53,95%CI 1.57-27.32)与达到血清尿酸目标相关。
  • 血清尿酸在6个月时下降0.1 mg/dL(p=0.52),12个月时下降0.2 mg/dL(p=0.01)。
  • 基线血清尿酸>6 mg/dL者降幅更大:6个月下降0.6 mg/dL、12个月下降0.8 mg/dL(均p<0.001);血清尿酸变化独立于代谢控制改善、体重下降或基线GLP-1受体激动剂/SGLT2抑制剂使用。

关键数值与推荐

  • 主要终点为随访12个月时血清尿酸<6 mg/dL。
  • 达到血清尿酸<6 mg/dL的关联因素:基线血清尿酸≥7 mg/dL(OR 4.54,95%CI 1.08-19.25)与从DPP-4抑制剂转换(OR 6.53,95%CI 1.57-27.32)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on serum urate (SU) levels in people with type 2 diabetes (PWT2D) is limited. This study investigates the effect of oral semaglutide on SU levels. METHODS: Retrospective, observational study including PWT2D who were prescribed oral semaglutide. The primary endpoint was achieving SU levels below 6 mg/dL at 12 months of follow-up (FU). Secondly, we assessed baseline factors associated with achieving SU levels of <6 mg/dL and average reductions in SU levels. RESULTS: The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors). Baseline SU was 5.2 mg/dL, 66.1 % had SU levels <6 mg/dL, and 23.7 % had hyperuricemia. Under oral semaglutide, 70.7 % and 76 % showed SU <6 mg/dL at 6 and 12 months, respectively. After multivariate adjustment, only SU ≥7 mg/dL (OR 4.54, 95 %CI 1.08-19.25) and switching from a DPP-4 inhibitor (OR 6.53, 95 %CI 1.57-27.32) were associated with achieving the SU target. SU decreased by 0.1 mg/dL after 6 months (p = 0.52) and by 0.2 mg/dL (p = 0.01) at 12 months FU. Greater reductions were observed in those with baseline SU >6 mg/dL (0.6 mg/dL and 0.8 mg/dl, respectively; all p < 0.001). Changes in SU levels were independent of improved metabolic control, weight loss, or baseline use of GLP-1 RAs or SGLT2 inhibitors. CONCLUSION: Oral semaglutide in real-world settings showed a modest reduction in SU levels in PWT2D, particularly linked to baseline hyperuricemia (with notable reduction figures) and switching from DPP-4 inhibitors.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Moreno-Pérez O, Tejera-Muñoz A, Carreño-Valdivia R, et al. Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study). Semin Arthritis Rheum. 2025. PMID: 40816061. doi:10.1016/j.semarthrit.2025.152807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。